UniProtKB/Swiss-Prot Q32NC0: Variant p.Thr132Ala

UPF0711 protein C18orf21
Gene: C18orf21
Feedback?

Variant information Variant position:

132 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Alanine (A) at position 132 (T132A, p.Thr132Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (T) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs2276314 [ dbSNP | Ensembl ]

Sequence information Variant position:

132 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

220 The length of the canonical sequence.
Location on the sequence:

KHHGKSRSFVSTLKSNPATP T SKLSLKTPERRTANPNHDMS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KHHGKSRSFVSTLKSNPA-TPTSKLSLKTPERR---TANPNHDMS

Mouse                         RHHGKSRSFLWALKSNAA-TAANKASPKTPKRTAPGSANLG

Rat                           RHHGKSRSFLSALRSSRAASAASKASPKTPKRAAAGSTNIS

Bovine                        KHHGKSRSFLSALKSNPT-TPTSKLSLKTPERKTPSSANLN

Zebrafish                     RQPGMNRELLVSLSKHKS-TPGSASKHRTPQ-----TVNWA

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 220	UPF0711 protein C18orf21
Region	117 – 181	Disordered
Compositional bias	120 – 181	Polar residues
Modified residue	126 – 126	Phosphoserine
Modified residue	130 – 130	Phosphothreonine
Modified residue	139 – 139	Phosphothreonine

Literature citations
Screening and cloning of the target genes transactivated by hepatitis B virus X protein by microarray assay.
Cheng J.; Liu Y.; Hong Y.; Wang J.-J.; Yang Q.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); VARIANT ALA-132; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2); VARIANT ALA-132;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.